Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …

Abstract M2-polarized, pro-tumoral tumor-associated macrophages (TAMs) express the
interleukin-4 receptor (IL4R) at higher levels compared with M1-polarized, anti-tumoral …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical
trials. Success has been reported in non–small and small cell lung carcinomas and …

Tumor-associated macrophages (TAMs) are major innate immune cells that constitute up to
50% of the cell mass of human tumors. TAMs are highly heterogeneous cells that originate …

Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability …

Simple Summary Tumor-Associated Macrophages (TAMs) play an important role in the
development of tumors, modulation of neoangiogenesis, immune suppression, and …

Taxol®, which is also known as paclitaxel, is a chemotherapeutic agent widely used to treat
different cancers. Since the discovery of its antitumoral activity, Taxol® has been used to …

Tumor-associated macrophages (TAMs) are abundant, nearly accounting for 30–50% of
stromal cells in the tumor microenvironment. TAMs exhibit an immunosuppressive M2-like …